Announced
Completed
Financials
Tags
Completed
Acquisition
Friendly
biotechnology
Private
Majority
Single Bidder
chemical synthesis services
France
biotherapeutics
Cross Border
Private Equity
Biotechnology
Synopsis
Univercells, a biotechnology company, completed the acquisition of SynHelix, a biotechnology company developing scalable and automated DNA synthesis, from AdBio partners, a life sciences venture capital firm. Financial terms were not disclosed. “The development of SynHelix’s synthetic DNA production platform is highly complementary to Quantoom’s flagship RNA platform, as linear DNA is one of the critical inputs of RNA production. This deal will unlock expertise, knowledge and IP on de novo DNA synthesis, where the SynHelix team holds valuable experience. Both companies’ founders, employees and investors share the same vision and mission, aiming at making new and complex biopharmaceuticals available to all and strongly believe in technology-driven affordability. In addition, the acquisition enables us to tap into the dynamic French biotech ecosystem,” José Castillo, Quantoom Biosciences CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.